Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting

AIDS

Volumn 13, Issue 14, 1999, Pages 1863-1871

  Harrigan, P Richard ^a,d   Hertogs, Kurt ^b   Verbiest, Werner ^b   Pauwels, Rudi ^b   Larder, Brendan ^c   Kemp, Sharon ^c   Bloor, Stuart ^c   Yip, Benita ^a   Hogg, Robert ^a   Alexander, Christopher ^a   Montaner, Julio S G ^a  

^a Brit Columbia Ctr Excell HIV/AIDS   (Canada)

^b Virco BVBA   (Belgium)

^c Virco UK Ltd   (United Kingdom)

^d ST PAUL S HOSPITAL   (Canada)

Author keywords

HIV 1; Protease inhibitor; Resistance; Ritonavir; Saquinavir

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VOMITING;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RESIDENCE CHARACTERISTICS; RITONAVIR; SAQUINAVIR; VIRAL LOAD;

EID: 0032750440     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910010-00008     Document Type: Article

References (24)

1. Moyle GJ. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 1997, 40:765-767.
2. Kuritzkes DR. Clinical significance of drug resistance in HIV-1 infection. AIDS 1996, 10(suppl 5):S27-S31.
3. Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994, 75:951-957.
4. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998, 279:1984-1991.
5. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
6. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996, 173:1379-1387.
7. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998, 72:5154-5164.
8. Craig C, Race E, Sheldon J, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998, 12:1611-1618.
9. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:452-464.
10. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997, 41:654-660.
11. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 1997, 11:F95-F99.
12. Deeks SG, Grant RM, Beatty GW, et al. Activity of ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
13. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998, 12:619-624.
14. Kaufmann GR, Duncombe C, Cunningham P, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998, 12:1625-1630.
15. Cameron W, Sun E, Markowitz M, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. XI International Conference on AIDS. Vancouver, Canada, July 1996 [abstract Th.B.934].
16. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
17. Hertogs K. Larder BA, Mellors J et al. Patterns of phenotypic and genotypic cross-resistance among protease inhibitors in over 1000 clinical HIV-1 isolates. 72th World AIDS Conference. Geneva, June 1998 [abstract 42195].
18. Jahnke N, Seminari E, Hogg RS et al. Antiretroviral effect of two different dose regimens of ritonavir and saquinavir among HIV infected adults in a population-based setting. Antiviral Therapy (in press).
19. Hertogs K, De Bethune MP, Miller V et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
20. Pauwels R. Hertogs K, Kemp S. et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. Second International Workshop on HIV Drug Resistance, Treatment Strategies. Lake Maggiore, Italy, June 1998 (abstract 51].
21. Neave HR. Worthington PL Distribution-free tests. London, Routledge. 1998.
22. Zolopa AR, Shafer R, Warford A, et al. HIV genotypic predictors of antiretroviral response to saquinavir (SQV)/ritonavir (RTV) therapy in patients who have failed prior protease inhibitors (PIs): a clinical cohort study. 12th World AIDS Conference. Geneva, June 1998 [abstract 32287].
23. Zolopa AR, Shafer RW, Warford A, Montoya JC, Katzenstein D, Merigan TC. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Second International Workshop on HIV Drug Resistance & Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 54].
24. Patick AK, Zhang M, Hertogs K et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Second International Workshop on HIV Drug Resistance & Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 57].